Celldex Therapeutics, Inc. (CLDX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 11:15AM EDT. Market open.
| Previous close | 41.06 |
| Open | 41.60 |
| Bid | 40.04 x 100 |
| Ask | 46.47 x 100 |
| Day's range | 40.13 - 41.66 |
| 52-week range | 22.11 - 53.18 |
| Volume | |
| Avg. volume | 930,214 |
| Market cap | 2.648B |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Simply Wall St.
Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Celldex Therapeutics ( NASDAQ:CLDX ) First Quarter 2024 Results Key Financial Results Net loss: US$32.8m (loss widened...
- Zacks
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
© 2024 Yahoo. All rights reserved.